Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 223

The DOI matches its Crossref record.

Complicated Skin and Skin‐Structure Infections and Catheter‐Related Bloodstream Infections: Noninferiority of Linezolid in a Phase 3 Study

Wilcox, Mark H., Tack, Kenneth J., Bouza, Emilio, Herr, Daniel L., Ruf, Bernhard R., Ijzerman, M. Marian, Croos‐Dabrera, Rodney V., Kunkel, Mark J., Knirsch, Charles·2009·Clinical Infectious Diseases

Abstract

BACKGROUND: Catheter-related bloodstream infection (CRBSI) causes substantial morbidity and mortality, but few randomized, controlled studies have been conducted to guide therapeutic interventions. METHODS: To determine whether linezolid would be noninferior to vancomycin in patients with CRBSI, we conducted an open-label, multicenter, comparative study. Patients with suspected CRBSI were randomized to receive linezolid or vancomycin (control group). The primary end point was microbiologic outcome at test of cure 1-2 weeks after treatment, as assessed by step-down procedure. The first analysis population was complicated skin and skin structure infection (cSSSI) in patients with suspected CRBSI; patients with CRBSI were analyzed if noninferiority criteria (lower bound of the 95% confidence interval [CI] not outside -15%) were met. RESULTS: Noninferiority criteria were met for cSSSI (microbiologic success rate for linezolid recipients, 89.6% [146 for 163 patients]; for the control group, 89.9% [134 of 149]; 95% CI, -7.1 to 6.4) and CRBSI (for linezolid recipients, 86.3% [82 of 95]; for the control group, 90.5% [67 of 74]; 95% CI, -13.8 to 5.4). The frequency and severity of adverse events were similar between groups. Mortality rates were 10.4% for linezolid recipients (28 of 269 patients) and 10.1% for control subjects (26 of 257) in the modified intent-to-treat population (i.e., all patients with gram-positive baseline culture) through test of cure, and they were 21.5% for linezolid recipients (78 of 363) and 16.0% for the control group (58 of 363; 95% CI, -0.2 to 11.2) for all treated patients through poststudy treatment day 84. CONCLUSIONS: Linezolid demonstrated microbiologic success rates noninferior to those for vancomycin in patients with cSSSIs and CRBSIs caused by gram-positive organisms. Patients with catheter-related infections must be carefully investigated for the heterogeneous underlying causes of high morbidity and mortality, particularly for infections with gram-negative organisms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/595686

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 223

Metadata

Authors
Wilcox, M. H., Tack, K. J., Bouza, E., Herr, D. L., Ruf, B. R., Ijzerman, M. M., Croos‐Dabrera, R. V., Kunkel, M. J., & Knirsch, C.
Venue
Clinical Infectious Diseases
Published
2009-01-15
Volume
48
Issue
2
Pages
203-212
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2152652294
Cited by
223
References
0
FWCI
28.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Complicated Skin and Skin‐Structure Infections and Catheter‐Related Bloodstream Infections: Noninferiority of Linezolid in a Phase 3 Study. https://app.cochat.ai/papers/10.1086/595686
The paper
Wilcox, M. H., Tack, K. J., Bouza, E., Herr, D. L., Ruf, B. R., Ijzerman, M. M., Croos‐Dabrera, R. V., Kunkel, M. J., & Knirsch, C. (2009). Complicated Skin and Skin‐Structure Infections and Catheter‐Related Bloodstream Infections: Noninferiority of Linezolid in a Phase 3 Study. Clinical Infectious Diseases. https://doi.org/10.1086/595686

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.